---
document_datetime: 2025-09-05 15:10:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zemcelpro-epar-all-authorised-presentations_en.pdf
document_name: zemcelpro-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6806562
conversion_datetime: 2025-12-27 21:06:01.16453
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength                                                               | Pharmaceutical Form     | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                                                                     |
|------------------|-------------------|------------------------------------------------------------------------|-------------------------|---------------------------|-----------------------|---------------------------|-------------------------------------------------------------------------------|
| EU/1/25/1960/001 | Zemcelpro         | ≥ 0.23 x 10⁶ viable CD34+ cells/ml / ≥ 0.53 x 10⁶ viable CD3+ cells/ml | Dispersion for infusion | Intravenous use           | bag (EVA)             | 20 ml                     | Up to 8 bags (up to 4 bags of dorocubicel + 4 bags of unexpanded CD34- cells) |